The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone

被引:85
作者
Sylvestre, DL
Litwin, AH
Clements, BJ
Gourevitch, MN
机构
[1] Org Achieve Solut Subst Abuse, OASIS, Oakland, CA 94612 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Montefiore Med Ctr, Dept Psychiat & Behav Sci, Div Subst Abuse, Bronx, NY 10467 USA
[4] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
[5] NYU, Sch Med, Dept Med, Div Gen Internal Med, New York, NY USA
关键词
hepatitis C; barrier; psychiatric disease; drug use; abstinence;
D O I
10.1016/j.jsat.2005.06.002
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Although most cases of hepatitis C virus (HCV) infection are associated with injection drug use, there are few data regarding the impact of putative barriers such as psychiatric disease and intercurrent drug use on HCV treatment outcomes. To define the impact of characteristics often cited as reasons for withholding HCV treatment, we studied HCV treatment in a real world sample of 76 recovering heroin users maintained on methadone. Overall, 21 (28%) had a sustained virological response and 18 (24%) discontinued treatment early. Although there was a modest decrement in response rates in patients reporting a preexisting psychiatric history (p =.01), neither intercurrent drug use nor short duration of pretreatment drug abstinence led to significant reductions in virological outcomes (p =.09 and p =.18, respectively.) We conclude that injection drug users can be safely and effectively treated for HCV despite multiple barriers to treatment when they are treated in a setting that can address their special needs. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 25 条
[1]   Epidemiology of hepatitis C [J].
Alter, MJ .
HEPATOLOGY, 1997, 26 (03) :S62-S65
[2]   The importance of preventing hepatitis C virus infection among injection drug users in the United States [J].
Alter, MJ ;
Moyer, LA .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 :S6-S10
[4]   Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[5]   Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy [J].
Capuron, L ;
Raison, CL ;
Musselman, DL ;
Lawson, DH ;
Nemeroff, CB ;
Miller, AH .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (07) :1342-1345
[6]   Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up [J].
Dalgard, O ;
Bjoro, K ;
Hellum, K ;
Myrvang, B ;
Skaug, K ;
Gutigard, B ;
Bell, H .
EUROPEAN ADDICTION RESEARCH, 2002, 8 (01) :45-49
[7]   Treatment of chronic hepatitis C in active drug users [J].
Davis, GL ;
Rodrigue, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :215-217
[8]   Prevention and treatment of hepatitis C in injection drug users [J].
Edlin, BR .
HEPATOLOGY, 2002, 36 (05) :S210-S219
[9]   Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C [J].
Fontana, RJ .
DIGESTIVE DISEASES, 2000, 18 (03) :107-116
[10]  
Ho SB, 2001, AM J GASTROENTEROL, V96, P157